Skip to main content
Premium Trial:

Request an Annual Quote

On Heels of Successful MiSeqDx Launch, Illumina Plans to Submit HiSeq 2500, NIPT Assay to FDA


Illumina said this week that it plans this year to submit for US Food and Drug Administration clearance its HiSeq 2500 platform coupled with Verinata Health's Verifi test for noninvasive prenatal fetal aneuploidy screening.

In a presentation at the JP Morgan Healthcare conference in San Francisco, President and CEO Jay Flatley said the company plans to file the instrument for clearance in 2014 and that the Verifi test would be the first assay. Clearance of the HiSeq 2500 would enable other third parties to submit their test on the system, he said.

Late last year, Illumina received FDA clearance of its MiSeqDx system and three assays — a cystic fibrosis screening assay covering 139 known pathogenic variants, a cystic fibrosis diagnostic covering the entire CFTR gene, and its Universal Kit that includes reagents for users to develop their own assays.

Flatley said this week that in the fourth quarter of 2013 the firm took orders for 300 MiSeq systems, eight of which were for the FDA-cleared MiSeqDx version, despite only receiving clearance in late November.

The MiSeqDx system "received clearance on key analytic claims," Flatley said, which will not only enable customers to use the cleared cystic fibrosis assays, but will also allow them to "submit their own assay methods on top of a cleared platform."

"Very importantly," aside from an assay that screens 139 known pathogenic variants, the firm "received clearance for a second version that sequences the entire CF gene without claiming any specific variants," Flatley said, adding that this is a "significant step forward in how the FDA clears products, given that there's an essentially infinite number of interpretations possible that could be made from sequencing the entire gene."

As such, Illumina "made a strategic decision to submit the HiSeq 2500 for FDA clearance with the Verinata NIPT test as the first application," Flatley said.

Unlike the firm's MiSeqDx submission, the HiSeq 2500 submission will not include a Universal Kit. The company did not elaborate on potential future assays it would submit for FDA clearance on the 2500.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.